Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsRadiation InjuriesRadiation DosageNeoplasmsRadiation, IonizingCombined Modality TherapyDose-Response Relationship, RadiationDoxorubicinCell Line, TumorCisplatinRadiotherapyChemotherapy, AdjuvantRadiation ToleranceDrug Screening Assays, AntitumorRadiotherapy DosageDrug Resistance, NeoplasmBreast NeoplasmsRadiationAntineoplastic Agents, PhytogenicRadiation OncologyApoptosisTreatment OutcomeRadiation ProtectionRadiotherapy, ConformalAntibiotics, AntineoplasticLung NeoplasmsRadiotherapy, Intensity-ModulatedRadiation MonitoringCell SurvivalRadiotherapy, AdjuvantPaclitaxelEtoposideDose FractionationDrug Resistance, MultipleDrug Delivery SystemsMice, NudeXenograft Model Antitumor AssaysCyclophosphamideTumor Cells, CulturedRadiotherapy Planning, Computer-AssistedRadiation PneumonitisNeoplasm StagingNeoplasm Recurrence, LocalSurvival AnalysisAntimetabolites, AntineoplasticRadiation-Sensitizing AgentsDisease-Free SurvivalProstatic NeoplasmsDose-Response Relationship, DrugDrug CarriersVinblastinePrognosisCamptothecinNeoplasms, Radiation-InducedSurvival RateTime FactorsBrachytherapyFluorouracilDNA DamageBrain NeoplasmsColonic NeoplasmsAdenocarcinomaP-GlycoproteinAntineoplastic Agents, AlkylatingCell ProliferationClinical Trials as TopicRadiometryOvarian NeoplasmsGene Expression Regulation, NeoplasticHead and Neck NeoplasmsGamma RaysCarcinoma, Squamous CellMethotrexateNeoplasm MetastasisRadiation Injuries, ExperimentalVomitingDrug Administration ScheduleOrganoplatinum CompoundsProdrugsDrug SynergismRadiosurgeryFollow-Up StudiesMitomycinCranial IrradiationTaxoidsDeoxycytidineCell CycleCarcinoma, Non-Small-Cell LungNauseaNeoplasm TransplantationCosmic RadiationDaunorubicinInhibitory Concentration 50Neoplasm ProteinsPlatinumTumor BurdenCarcinomaTumor Suppressor Protein p53Radiotherapy, Computer-Assisted